References: Antimicrobial dosage modification in kidney impairment

  • Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74(8):839-54. https://pubmed.ncbi.nlm.nih.gov/24846578/
  • Boucher BA, Hudson JQ, Hill DM, Swanson JM, Wood GC, Laizure SC, et al. Pharmacokinetics of imipenem/cilastatin burn intensive care unit patients undergoing high-dose continuous venovenous hemofiltration. Pharmacotherapy 2016;36(12):1229-37. https://www.ncbi.nlm.nih.gov/pubmed/27862103
  • Cotton A, Franklin BD, Brett S, Holmes A. Using imipenem and cilastatin during continuous renal replacement therapy. Pharm World Sci 2005;27(5):371-5. https://www.ncbi.nlm.nih.gov/pubmed/16341743
  • Cunha BA, Cunha CB, Lam B, Giuga J, Chin J, Zafonte VF, et al. Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications. Eur J Clin Microbiol Infect Dis 2017;36(7):1213-6. https://www.ncbi.nlm.nih.gov/pubmed/28155015
  • Custodio JM, Fordyce M, Garner W, Vimal M, Ling KH, Kearney BP, et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother 2016;60(9):5135-40. https://www.ncbi.nlm.nih.gov/pubmed/27216057
  • Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002;72(2):142-50. https://www.ncbi.nlm.nih.gov/pubmed/12189361
  • De Schuyter K, Colin PJ, Vanommeslaeghe F, Delanghe S, De Cock P, Veys N, et al. Optimizing Amoxicillin/Clavulanic Acid Dosing Regimens in Patients on Maintenance High-Flux Hemodialysis. Am J Kidney Dis 2021;78(1):153-6. https://www.ncbi.nlm.nih.gov/pubmed/33460691
  • Duke C, Parker SL, Zam BB, Chiong F, Sajiv C, Pawar B, et al. Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment? J Antimicrob Chemother 2024. https://www.ncbi.nlm.nih.gov/pubmed/39255245
  • Eron JJ, Jr., Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, et al. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV 2018. https://www.ncbi.nlm.nih.gov/pubmed/30555051
  • Franck B, Autmizguine J, Marquet P, Ovetchkine P, Woillard JB. Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. Clin Pharmacol Ther 2022;112(2):233-76. https://pubmed.ncbi.nlm.nih.gov/34596243/
  • Gattringer R, Meyer B, Heinz G, Guttmann C, Zeitlinger M, Joukhadar C, et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother 2006;58(2):367-71. https://www.ncbi.nlm.nih.gov/pubmed/16782745
  • Geerlings CJ, de Man P, Rietveld AP, Touw DJ, Cohen Tervaert JW. A practical thrice weekly Ertapenem dosage regime for chronic hemodialysis patients? Clin Nephrol 2013;80(4):312. https://www.ncbi.nlm.nih.gov/pubmed/24060141
  • Geerts AF, Eppenga WL, Heerdink R, Derijks HJ, Wensing MJ, Egberts TC, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. Eur J Clin Pharmacol 2013;69(9):1701-7. https://www.ncbi.nlm.nih.gov/pubmed/23660771
  • Gervasoni C, Bergia R, Cozzi V, Clementi E, Cattaneo D. Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. J Antimicrob Chemother 2015;70(10):2918-20. https://www.ncbi.nlm.nih.gov/pubmed/26142409
  • Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009;29(5):562-77. https://pubmed.ncbi.nlm.nih.gov/19397464/
  • Hsaiky LM, Salinitri FD, Wong J, Jennings ST, Desai NH, Lobkovich AM, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Nephrol Dial Transplant 2019;34(10):1766-72. https://www.ncbi.nlm.nih.gov/pubmed/29992286
  • Humbert G, Spyker DA, Fillastre JP, Leroy A. Pharmacokinetics of amoxicillin: Dosage nomogram for patients with impaired renal function. Antimicrob Agents Chemother 1979;15(1):28-33. https://www.ncbi.nlm.nih.gov/pubmed/426503/
  • Jarrell AS, Crow JR, Strout SE, Kruer RM, Toman LP, Dioverti-Prono MV, et al. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. Clin Infect Dis 2021;73(1):101-6. https://www.ncbi.nlm.nih.gov/pubmed/32379860
  • Jones TE. Oseltamivir-Current Dosing Recommendations Reduce the Therapeutic Benefit in Patients With Mild to Moderate Renal Function and/or Large Body Mass: A Review of the Literature With Recommendations to Optimize Dosing, Including the Use of Therapeutic Drug Monitoring. Ther Drug Monit 2021;43(1):103-7. https://pubmed.ncbi.nlm.nih.gov/32947554/
  • Kamal MA, Brennan BJ, Subramoney V, Lien YT, Morcos PN, Frey N, et al. Identification of new oral dosing regimens for the neuraminidase inhibitor oseltamivir in patients with moderate and severe renal impairment. Clin Pharmacol Drug Dev 2015;4(5):326-36. https://www.ncbi.nlm.nih.gov/pubmed/27137141
  • Karie S, Launay-Vacher V, Janus N, Izzedine H, Deray G. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant 2006;21(12):3606-8. https://www.ncbi.nlm.nih.gov/pubmed/16799172
  • Kawasuji H, Tsuji Y, Ogami C, Kimoto K, Ueno A, Miyajima Y, et al. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients. BMC Pharmacol Toxicol 2021;22(1):13. https://www.ncbi.nlm.nih.gov/pubmed/33663616
  • Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150. https://kdigo.org/guidelines/ckd-evaluation-and-management/
  • Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-beta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care 2015;19(1):32. https://www.ncbi.nlm.nih.gov/pubmed/25645660
  • Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet 2005;44(3):221-35. https://pubmed.ncbi.nlm.nih.gov/15762766/
  • Li L, Li X, Xia Y, Chu Y, Zhong H, Li J, et al. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy. Front Pharmacol 2020;11:786. https://pubmed.ncbi.nlm.nih.gov/32547394/
  • Lin SY, Chiu YW, Lu PL, Hwang SJ, Chen TC, Hsieh MH, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. J Microbiol Immunol Infect 2019;52(1):158-62. https://www.ncbi.nlm.nih.gov/pubmed/29907535
  • Lin SY, Feng JY, Lee CY, Lin YC, Chou YH, Lin KY, et al. Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study. Antimicrob Agents Chemother 2021;65(3). https://www.ncbi.nlm.nih.gov/pubmed/33361292
  • Muilwijk EW, de Lange DW, Schouten JA, Wasmann RE, Ter Heine R, Burger DM, et al. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrob Agents Chemother 2020;64(10). https://www.ncbi.nlm.nih.gov/pubmed/32816723
  • Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016;63(7):e147-e95. https://www.ncbi.nlm.nih.gov/pubmed/27516382
  • Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013;47(1):106-11. https://www.ncbi.nlm.nih.gov/pubmed/23341159
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Appendix B, Table 12. Antiretroviral Dosing Recommendations in Adults with Renal or Hepatic Insufficiency. In: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Rockville, Maryland: Department of Health and Human Services; 2024. Accessed 15 March 2024. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Rockville, Maryland: Department of Health and Human Services; 2024. Accessed 15 March 2023. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/
  • Patel K, Rayner CR, Giraudon M, Kamal MA, Morcos PN, Robson R, et al. Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. Br J Clin Pharmacol 2015;79(4):624-35. https://www.ncbi.nlm.nih.gov/pubmed/25289522
  • Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 2011;55(12):5868-73. https://www.ncbi.nlm.nih.gov/pubmed/21930888
  • Renaud CJ, Lin X, Subramanian S, Fisher DA. High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia. Hemodial Int 2011;15(1):63-8. https://www.ncbi.nlm.nih.gov/pubmed/21105995
  • Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc 2016;64(4):798-805. https://www.ncbi.nlm.nih.gov/pubmed/27100576
  • Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011;55(5):1867-73. https://www.ncbi.nlm.nih.gov/pubmed/21357301
  • Shah A, Lettieri J, Blum R, Millikin S, Sica D, Heller AH. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. J Antimicrob Chemother 1996;38(1):103-16. https://www.ncbi.nlm.nih.gov/pubmed/8858462
  • Singh N, Gandhi S, McArthur E, Moist L, Jain AK, Liu AR, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ 2015;187(9):648-56. https://www.ncbi.nlm.nih.gov/pubmed/25918178
  • Sinnollareddy M, Peake SL, Roberts MS, Playford EG, Lipman J, Roberts JA. Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opin Drug Metab Toxicol 2011;7(11):1431-40. https://www.ncbi.nlm.nih.gov/pubmed/21883033
  • Smit C, Sen S, von Dach E, Karmime A, Lescuyer P, Tonoli D, et al. Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure. Antibiotics (Basel) 2022;11(9). https://www.ncbi.nlm.nih.gov/pubmed/36139969
  • Tsai D, Zam BB, Tongs C, Chiong F, Sajiv C, Pawar B, et al. Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study. J Antimicrob Chemother 2023;78(8):1963-73. https://www.ncbi.nlm.nih.gov/pubmed/37367723
  • Tsuji Y, Holford NHG, Kasai H, Ogami C, Heo YA, Higashi Y, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol 2017;83(8):1758-72. https://www.ncbi.nlm.nih.gov/pubmed/28186644
  • Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review. Int J Antimicrob Agents 2015;46(4):362-6. https://www.ncbi.nlm.nih.gov/pubmed/26253129
  • Ueng YF, Wang HJ, Wu SC, Ng YY. A practical thrice weekly ertapenem in hemodialysis patients. Antimicrob Agents Chemother 2019;63(12). https://www.ncbi.nlm.nih.gov/pubmed/31527026
  • Wang U, Yang A, Dong M, Busque S. Safety and effectiveness of valganciclovir for cytomegalovirus prophylaxis in solid organ transplant patients on hemodialysis [abstract number: A587]. Am J Transplant 2013;13(Suppl 5). https://atcmeetingabstracts.com/abstract/safety-and-effectiveness-of-valganciclovir-for-cytomegalovirus-prophylaxis-in-solid-organ-transplant-patients-on-hemodialysis/